What is Lifesci Capital’s Estimate for AVDL Q2 Earnings?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Equities research analysts at Lifesci Capital issued their Q2 2025 earnings per share (EPS) estimates for Avadel Pharmaceuticals in a research note issued on Monday, March 3rd. Lifesci Capital analyst M. Belghiti expects that the company will earn $0.02 per share for the quarter. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share.

Other equities analysts also recently issued research reports about the company. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of Avadel Pharmaceuticals in a research note on Monday. Piper Sandler dropped their target price on Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Deutsche Bank Aktiengesellschaft began coverage on Avadel Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $12.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of Avadel Pharmaceuticals in a research report on Tuesday. Finally, UBS Group dropped their target price on Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, January 13th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Avadel Pharmaceuticals currently has an average rating of “Buy” and an average target price of $19.88.

Avadel Pharmaceuticals Trading Up 3.0 %

Avadel Pharmaceuticals stock opened at $7.87 on Thursday. Avadel Pharmaceuticals has a 12 month low of $7.39 and a 12 month high of $19.09. The business’s 50 day simple moving average is $8.72 and its 200 day simple moving average is $11.48. The company has a market cap of $758.37 million, a price-to-earnings ratio of -9.96 and a beta of 1.28.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC bought a new position in Avadel Pharmaceuticals in the third quarter valued at $31,000. Advisors Asset Management Inc. increased its stake in Avadel Pharmaceuticals by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 7,921 shares of the company’s stock valued at $104,000 after acquiring an additional 2,846 shares during the last quarter. Hsbc Holdings PLC bought a new position in Avadel Pharmaceuticals in the fourth quarter valued at $113,000. Kazazian Asset Management LLC bought a new position in Avadel Pharmaceuticals in the fourth quarter valued at $126,000. Finally, Aigen Investment Management LP bought a new position in Avadel Pharmaceuticals in the third quarter valued at $160,000. Institutional investors own 69.19% of the company’s stock.

Insider Buying and Selling

In other Avadel Pharmaceuticals news, Director Linda Palczuk acquired 3,000 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were bought at an average price of $10.19 per share, for a total transaction of $30,570.00. Following the completion of the transaction, the director now owns 66,400 shares of the company’s stock, valued at approximately $676,616. This represents a 4.73 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Thomas S. Mchugh acquired 5,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was acquired at an average price of $10.49 per share, for a total transaction of $52,450.00. Following the transaction, the chief financial officer now directly owns 85,500 shares of the company’s stock, valued at $896,895. This represents a 6.21 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 55,579 shares of company stock worth $526,363. Corporate insiders own 4.80% of the company’s stock.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.